Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study ...

The study sought to evaluate the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive, once ...

Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder is a rare, genetically determined developmental and epileptic encephalopathy characterized by early-onset refractory seizures and severe ...

In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...

Following the results of an extensive survey by researchers at Arizona State University and the University of Texas-Houston, medical professionals and parents now have a better guide for treating ...

There are many types of epilepsy, a brain disorder that causes recurrent seizures or periods of altered behaviors or sensations. Around one percent of the world's population is thought to be impacted, ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating ...

A surgical treatment commonly used to reduce epileptic seizures in adults also is effective and safe for children, according to a new study. The study is one of the first to investigate responsive ...

Two new models could solve a problem that's long frustrated millions of people with epilepsy and the doctors who treat them: how to find precisely where seizures originate to treat exactly that part ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among those deemed “treatment sensitive,” 69.4% ...